Sight Sciences, Inc. (NASDAQ:SGHT – Get Rating) – Analysts at William Blair issued their Q1 2024 earnings per share (EPS) estimates for Sight Sciences in a report issued on Thursday, June 15th. William Blair analyst M. Kaczor anticipates that the company will post earnings of ($0.30) per share for the quarter. The consensus estimate for Sight Sciences’ current full-year earnings is ($1.26) per share. William Blair also issued estimates for Sight Sciences’ Q2 2024 earnings at ($0.26) EPS, Q3 2024 earnings at ($0.24) EPS and Q4 2024 earnings at ($0.20) EPS.
Separately, Bank of America cut their target price on shares of Sight Sciences from $13.00 to $10.00 in a research note on Tuesday, June 6th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $14.00.
Sight Sciences Price Performance
Sight Sciences (NASDAQ:SGHT – Get Rating) last released its earnings results on Thursday, May 4th. The company reported ($0.35) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.06. The firm had revenue of $18.82 million during the quarter, compared to the consensus estimate of $18.99 million. Sight Sciences had a negative return on equity of 47.71% and a negative net margin of 106.34%.
Institutional Inflows and Outflows
A number of large investors have recently made changes to their positions in the stock. Charles Schwab Investment Management Inc. raised its position in Sight Sciences by 0.9% in the first quarter. Charles Schwab Investment Management Inc. now owns 185,096 shares of the company’s stock worth $1,618,000 after purchasing an additional 1,627 shares in the last quarter. Swiss National Bank raised its position in Sight Sciences by 7.3% in the first quarter. Swiss National Bank now owns 28,000 shares of the company’s stock worth $324,000 after purchasing an additional 1,900 shares in the last quarter. Huntington National Bank acquired a new position in Sight Sciences in the fourth quarter worth about $31,000. Bank of America Corp DE raised its position in Sight Sciences by 3.2% in the first quarter. Bank of America Corp DE now owns 104,044 shares of the company’s stock worth $909,000 after purchasing an additional 3,228 shares in the last quarter. Finally, Renaissance Technologies LLC increased its holdings in shares of Sight Sciences by 11.6% during the third quarter. Renaissance Technologies LLC now owns 31,586 shares of the company’s stock worth $201,000 after buying an additional 3,286 shares in the last quarter. Institutional investors and hedge funds own 50.31% of the company’s stock.
About Sight Sciences
Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists.
Read More
- Get a free copy of the StockNews.com research report on Sight Sciences (SGHT)
- Trading Stocks: RSI and Why it’s Useful
- Why Mosaic’s Price Targets May Be Understated
- Amazon And The AI War: iRobot Acquisition In Focus
- What Does Logitech CEO’s Abrupt Departure Mean?
- Ulta Beauty Stock Value is More Than Skin Deep
Receive News & Ratings for Sight Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sight Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
